FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Per thor Straten

Research Profile

Disorders

Chemicals & Drugs

Anatomy

Procedures

Co-author Network

Publications

TOP 3
Marco Donia; Eva Ellebæk; Morten Hansen; Trine Zeeberg Iversen; Sarah L Sendrup; Per thor Straten; Mads H Andersen; Inge Marie Svane
Methods to improve adoptive T-cell therapy for melanoma: IFN-γ enhances anticancer responses of cell products for infusion.
Morten Hansen; Gertrud Malene Hjortø; Niels Bent Larsen; Mads Hald Andersen; Marco Donia; Per thor Straten; Özcan Met; Inge Marie Svane
Comparison of clinical grade type 1 polarized and standard matured dendritic cells for cancer immunotherapy.
Jürgen C Becker; Eva-B Bröcker; Lidia Frey; Valeska Hofmeister-Müller; Eckhart Kämpgen; Andreas Opitz; Christiane Sandig; David Schrama; Harpreet Singh-Jasuja; Per thor Straten; Steffen Walter; Marion Wobser; Marc Zapatka; Mads Hald Andersen; Selma Ugurel
Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Per thor Straten (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Marco Donia; Eva Ellebæk; Morten Hansen; Trine Zeeberg Iversen; Sarah L Sendrup; Per thor Straten; Mads H Andersen; Inge Marie Svane
Methods to improve adoptive T-cell therapy for melanoma: IFN-γ enhances anticancer responses of cell products for infusion.
The Journal of investigative dermatology 2013;133(2):545-52.
2013: Morten Hansen; Gertrud Malene Hjortø; Niels Bent Larsen; Mads Hald Andersen; Marco Donia; Per thor Straten; Özcan Met; Inge Marie Svane
Comparison of clinical grade type 1 polarized and standard matured dendritic cells for cancer immunotherapy.
Vaccine 2013;31(4):639-46.
2012: Jürgen C Becker; Eva-B Bröcker; Lidia Frey; Valeska Hofmeister-Müller; Eckhart Kämpgen; Andreas Opitz; Christiane Sandig; David Schrama; Harpreet Singh-Jasuja; Per thor Straten; Steffen Walter; Marion Wobser; Marc Zapatka; Mads Hald Andersen; Selma Ugurel
Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma.
Cancer immunology, immunotherapy : CII 2012;61(11):2091-103.
2012: Niels Junker; Pia Kvistborg; Shamaila Munir; Per thor Straten; Inge Marie Svane; Mads Hald Andersen
A promiscuous survivin-derived T-cell epitope restricted to the HLA-A3 super-type alleles.
The Journal of investigative dermatology 2012;132(8):2115-8.
2012: Tania Køllgaard; Joost H van den Berg; Marco Donia; Per thor Straten
Eleventh international conference on progress in vaccination against cancer (PIVAC-11), 10-13 October 2011, Copenhagen, Denmark.
Cancer immunology, immunotherapy : CII 2012;61(8):1349-53.
2012: Marie Klinge Brimnes; Marco Donia; Anne Ortved Gang; Inge Marie Svane; Per thor Straten; Sine Reker Hadrup
Generation of autologous tumor-specific T cells for adoptive transfer based on vaccination, in vitro restimulation and CD3/CD28 dynabead-induced T cell expansion.
Cancer immunology, immunotherapy : CII 2012;61(8):1221-31.
2012: Rikke Sick Andersen; Arnold H Bakker; Thomas Mørch Frøsig; Pia Kvistborg; Rikke Lyngaa; Natasja W Pedersen; Schumacher Ton; Chengyi J Shu; Per thor Straten; Sine Reker Hadrup
Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers.
Nature protocols 2012;7(5):891-902.
2012: Rikke Sick Andersen; Marco Donia; Eva Ellebæk; Niels Junker; Rikke Lyngaa; Ton N Schumacher; Inge Marie Svane; Per thor Straten; Charlotte Albæk Thrue; Sine Reker Hadrup
Dissection of T-cell antigen specificity in human melanoma.
Cancer research 2012;72(7):1642-50.
2012: Eva Ellebaek; Mads Hald Andersen; Inge Marie Svane; Per thor Straten
Immunotherapy for metastatic colorectal cancer: present status and new options.
Scandinavian journal of gastroenterology 2012;47(3):315-24.
2012: Eva Ellebaek; Lotte Engell-Noerregaard; Sine Reker Hadrup; Lisbet Rosenkrantz Hölmich; Trine Zeeberg Iversen; Niels Junker; Mads Hald Andersen; Rikke Sick Andersen; Marco Donia; Per thor Straten; Özcan Met; Inge Marie Svane
Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients.
Journal of translational medicine 2012;10():169.
2012: Shamaila Munir; Per thor Straten; Inge Marie Svane; Marco Donia; Trine Zeeberg Iversen; Tobias Wirenfeldt Klausen; SK Larsen; Mads Hald Andersen
Natural CD4+ T-cell responses against indoleamine 2,3-dioxygenase.
PloS one 2012;7(4):e34568.
2012: Niels Junker; Tania Køllgaard; Pia Kvistborg; Mads Hald Andersen; Per thor Straten; Inge Marie Svane
Tumor associated antigen specific T-cell populations identified in ex vivo expanded TIL cultures.
Cellular immunology 2012;273(1):1-9.
2011: Per thor Straten; Mads Hald Andersen
HLA-A2-restricted survivin-derived T-cell responses.
Vaccine 2011;29(52):9582.
2011: Mikkel L Hansen; Katharina L M Kopp; Thorbjørn Krejsgaard; Thomas Litman; Niels Odum; Rolf Søkilde; Per thor Straten; Mariusz A Wasik; Anders Woetmann; Carsten Geisler; Karsten W Eriksen
IFN-α primes T- and NK-cells for IL-15-mediated signaling and cytotoxicity.
Molecular immunology 2011;48(15-16):2087-93.
2011: Per thor Straten; Mads Hald Andersen
A potential role of indoleamine 2,3-dioxygenase-specific T cells in leishmania vaccination.
The Journal of infectious diseases 2011;204(3):488-9.
2011: Niels Junker; Katalin Kiss; Christian Hjort Sørensen; Per thor Straten; Elo Andersen; Mads Hald Andersen; Sarah Louise Dombernowsky; MH Therkildsen; Christian von Buchwald; Lynn Wenandy; Inge Marie Svane
Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer.
Cytotherapy 2011;13(7):822-34.
2011: Per thor Straten; Mads Hald Andersen
Possible benefits of the targeting of indoleamine 2,3-dioxygenase (IDO) in hepatitis B vaccination.
Vaccine 2011;29(21):3728.
2011: J Bjoern; M K Brimnes; Mads Hald Andersen; Per thor Straten; Inge Marie Svane
Changes in peripheral blood level of regulatory T cells in patients with malignant melanoma during treatment with dendritic cell vaccination and low-dose IL-2.
Scandinavian journal of immunology 2011;73(3):222-33.
2011: Rikke Bæk Sørensen; Sine Reker Hadrup; Inge Marie Svane; Mads Christian Hjortsø; Per thor Straten; Mads Hald Andersen
Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators.
Blood 2011;117(7):2200-10.
2011: Rikke Sick Andersen; Rikke Bæk Sørensen; Cathrin Ritter; Inge Marie Svane; Jürgen C Becker; Per thor Straten; Mads Hald Andersen
Identification of a cyclin B1-derived CTL epitope eliciting spontaneous responses in both cancer patients and healthy donors.
Cancer immunology, immunotherapy : CII 2011;60(2):227-34.
2011: Niels Junker; Mads Hald Andersen; Per thor Straten; Inge Marie Svane
Characterization of ex vivo expanded tumor infiltrating lymphocytes from patients with malignant melanoma for clinical application.
Journal of skin cancer 2011;2011():574695.
2010: Redas Trepiakas; Annika Berntsen; Sine Reker Hadrup; Jon Bjørn; Poul F Geertsen; Per thor Straten; Mads Hald Andersen; Anders Elm Pedersen; Amir Soleimani; Torben Lorentzen; Julia S Johansen; Inge Marie Svane
Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial.
Cytotherapy 2010;12(6):721-34.
2010: Annika Berntsen; Marie Klinge Brimnes; Per thor Straten; Inge Marie Svane
Increase of circulating CD4+CD25highFoxp3+ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2010;33(4):425-34.
2010: Mads Hald Andersen; Niels Junker; Eva Ellebaek; Inge Marie Svane; Per thor Straten
Therapeutic cancer vaccines in combination with conventional therapy.
Journal of biomedicine & biotechnology 2010;2010():237623.
2009: Per thor Straten; Jürgen C Becker
Adoptive cell transfer in the treatment of metastatic melanoma.
The Journal of investigative dermatology 2009;129(12):2743-5.
2009: Rikke Baek Sørensen; Per thor Straten; Mads Hald Andersen
Comment on "Reduced cytotoxic function of effector CD8+ T cells is responsible for indoleamine 2,3-dioxygenase-dependent immune suppression".
Journal of immunology (Baltimore, Md. : 1950) 2009;183(10):6040.
2009: L Wenandy; T Kollgaard; A Letsch; R S Andersen; D Stather; T Seremet; I M Svane; L Vindeløv; Mads Hald Andersen; Per thor Straten
The 1170 A-P single-nucleotide polymorphism (SNP) in the Her-2/neu protein (HER2) as a minor histocompatibility antigen (mHag).
Leukemia 2009;23(10):1926-9.
2009: Jon Amund Kyte; Sissel Trachsel; Bente Risberg; Per thor Straten; Kari Lislerud; Gustav Gaudernack
Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination.
Cancer immunology, immunotherapy : CII 2009;58(10):1609-26.
2009: Mads Hald Andersen; Rikke Baek Sørensen; Marie K Brimnes; Inge Marie Svane; Jürgen C Becker; Per thor Straten
Identification of heme oxygenase-1-specific regulatory CD8+ T cells in cancer patients.
The Journal of clinical investigation 2009;119(8):2245-56.
2009: Rikke Baek Sørensen; Mikkel Faurschou; Lone Troelsen; David Schrama; Søren Jacobsen; Jürgen C Becker; Per thor Straten; Mads Hald Andersen
Melanoma inhibitor of apoptosis protein (ML-IAP) specific cytotoxic T lymphocytes cross-react with an epitope from the auto-antigen SS56.
The Journal of investigative dermatology 2009;129(8):1992-9.
2009: Sine Reker Hadrup; Arnold H Bakker; Chengyi J Shu; Rikke S Andersen; Jerre van Veluw; Pleun Hombrink; Emilie Castermans; Per thor Straten; Christian Blank; John B Haanen; Mirjam H Heemskerk; Schumacher Ton
Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers.
Nature methods 2009;6(7):520-6.
2009: Uta B Hofmann; Heike Voigt; Mads Hald Andersen; Per thor Straten; Jürgen C Becker; Andreas O Eggert
Identification and characterization of survivin-derived H-2Kb-restricted CTL epitopes.
European journal of immunology 2009;39(5):1419-24.
2009: Rikke Bæk Sørensen; Niels Junker; Alexei Kirkin; Heike Voigt; Inge Marie Svane; Jürgen C Becker; Per thor Straten; Mads Hald Andersen
The immunodominant HLA-A2-restricted MART-1 epitope is not presented on the surface of many melanoma cell lines.
Cancer immunology, immunotherapy : CII 2009;58(5):665-75.
2009: Rikke Bæk Sørensen; Rikke Sick Andersen; Inge Marie Svane; Lotte Engell-Noerregaard; Sine R Hadrup; Eva Balslev; Mads Hald Andersen; Per thor Straten
CD8 T-cell responses against cyclin B1 in breast cancer patients with tumors overexpressing p53.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(5):1543-9.
2009: Rikke Baek Sørensen; Linda Berge-Hansen; Niels Junker; Christina Aaen Hansen; Sine Reker Hadrup; Schumacher Ton; Inge Marie Svane; Jürgen C Becker; Per thor Straten; Mads Hald Andersen
The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase.
PloS one 2009;4(9):e6910.
2009: Lotte Engell-Noerregaard; Troels Holz Hansen; Mads Hald Andersen; Per thor Straten; Inge Marie Svane
Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters.
Cancer immunology, immunotherapy : CII 2009;58(1):1-14.
2008: Rikke Bæk Sørensen; Inge Marie Svane; Per thor Straten; Mads Hald Andersen
A survivin specific T-cell clone from a breast cancer patient display universal tumor cell lysis.
Cancer biology & therapy 2008;7(12):1885-7.
2008: Lynn Wenandy; Rikke Bæk Sørensen; Inge Marie Svane; Per thor Straten; Mads Hald Andersen
RhoC a new target for therapeutic vaccination against metastatic cancer.
Cancer immunology, immunotherapy : CII 2008;57(12):1871-8.
2008: Mads Hald Andersen; Rikke Bæk Sørensen; David Schrama; Inge Marie Svane; Jürgen C Becker; Per thor Straten
Cancer treatment: the combination of vaccination with other therapies.
Cancer immunology, immunotherapy : CII 2008;57(11):1735-43.
2008: Annika Berntsen; Redas Trepiakas; Lynn Wenandy; Poul F Geertsen; Per thor Straten; Mads H Andersen; Anders E Pedersen; Mogens H Claesson; Torben Lorentzen; Julia S Johansen; Inge Marie Svane
Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2008;31(8):771-80.
2008: Pia Kvistborg; Sine Reker Hadrup; Inge Marie Svane; Mads Hald Andersen; Per thor Straten
Characterization of a single peptide derived from cytochrome P450 1B1 that elicits spontaneous human leukocyte antigen (HLA)-A1 as well as HLA-B35 restricted CD8 T-cell responses in cancer patients.
Human immunology 2008;69(4-5):266-72.
2008: R S Andersen; L Wenandy; Rikke Bæk Sørensen; Per thor Straten; M H Andersen
Mcl-1 and anticancer vaccination: identification of an HLA-A2-restricted epitope.
Leukemia 2008;22(3):668-9.
2008: Cedrik Michael Britten; Cécile Gouttefangeas; Marij J P Welters; Graham Pawelec; Sven Koch; C Ottensmeier; A Mander; S Walter; Annette Paschen; Jan Muller-Berghaus; I Haas; Andreas Mackensen; Tania Køllgaard; Per thor Straten; M Schmitt; K Giannopoulos; R Maier; Hendrik Veelken; Cristina Bertinetti; Abdo Konur; Christoph Huber; S Stevanović; Thomas Wölfel; Sjoerd H van der burg
The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays.
Cancer immunology, immunotherapy : CII 2008;57(3):289-302.
2008: Lynn Wenandy; Rikke Bæk Sørensen; Lisa Sengeløv; Inge Marie Svane; Per thor Straten; Mads Hald Andersen
The immunogenicity of the hTERT540-548 peptide in cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(1):4-7.
2008: David Schrama; Heike Voigt; Andreas O Eggert; Rong Xiang; He Zhou; Schumacher Ton; Mads Hald Andersen; Per thor Straten; Ralph A Reisfeld; Jürgen C Becker
Immunological tumor destruction in a murine melanoma model by targeted LTalpha independent of secondary lymphoid tissue.
Cancer immunology, immunotherapy : CII 2008;57(1):85-95.
2007: Morgan G Mathieu; Ashley John Knights; Graham Pawelec; Catherine L Riley; Dorothee Wernet; François A Lemonnier; Per thor Straten; Ludmila Mueller; Robert C Rees; Stephanie McArdle
HAGE, a cancer/testis antigen with potential for melanoma immunotherapy: identification of several MHC class I/II HAGE-derived immunogenic peptides.
Cancer immunology, immunotherapy : CII 2007;56(12):1885-95.
2007: Mads Hald Andersen; Inge Marie Svane; Jürgen C Becker; Per thor Straten
The universal character of the tumor-associated antigen survivin.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(20):5991-4.
2007: Jon Amund Kyte; Gunnar Kvalheim; Kari Lislerud; Per thor Straten; Svein Dueland; Steinar Aamdal; Gustav Gaudernack
T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells.
Cancer immunology, immunotherapy : CII 2007;56(5):659-75.
2007: Rikke Bæk Sørensen; Sine Reker Hadrup; Tania Køllgaard; Inge Marie Svane; Per thor Straten; Mads Hald Andersen
Efficient tumor cell lysis mediated by a Bcl-X(L) specific T cell clone isolated from a breast cancer patient.
Cancer immunology, immunotherapy : CII 2007;56(4):527-33.
2007: Tatjana Dorn; Ursula Kuhn; Gerd Bungartz; Sebastian Stiller; Martina Bauer; Joachim W Ellwart; Thorsten Peters; Karin Scharffetter-Kochanek; Monika Semmrich; Melanie Laschinger; Bernhard Holzmann; Wolfgang E F Klinkert; Per thor Straten; Tania Køllgaard; Michael Sixt; Cord Brakebusch
RhoH is important for positive thymocyte selection and T-cell receptor signaling.
Blood 2007;109(6):2346-55.
2006: Sine Reker Hadrup; Otto Braendstrup; Grete Krag Jacobsen; Svend Mortensen; Lars Østergaard Pedersen; Tina Seremet; Mads Hald Andersen; Jürgen C Becker; Per thor Straten
Tumor infiltrating lymphocytes in seminoma lesions comprise clonally expanded cytotoxic T cells.
International journal of cancer. Journal international du cancer 2006;119(4):831-8.
2006: Rikke Bæk Sørensen; Ove Juul Nielsen; Per thor Straten; Mads Hald Andersen
Functional capacity of Mcl-1-specific cytotoxic T-cells.
Leukemia 2006;20(8):1457-8.
2006: Sine Reker Hadrup; Julie Gehl; Rikke Bæk Sørensen; Poul F Geertsen; Per thor Straten; Mads Hald Andersen
Persistence of survivin specific T cells for seven years in a melanoma patient during complete remission.
Cancer biology & therapy 2006;5(5):480-2.
2006: Monika Gad; Dorthe Lundsgaard; Stine Kjellev; Nanna Ny Kristensen; Tina Seremet; Per thor Straten; Mogens H Claesson
Reactivity of naive CD4+CD25- T cells against gut microflora in healthy mice.
International immunology 2006;18(5):817-25.
2006: Per thor Straten; Christina Dahl; David Schrama; Lars Østergaard Pedersen; Mads Hald Andersen; Tina Seremet; Eva-B Bröcker; Per Guldberg; Jürgen C Becker
Identification of identical TCRs in primary melanoma lesions and tumor free corresponding sentinel lymph nodes.
Cancer immunology, immunotherapy : CII 2006;55(5):495-502.
2006: Sine Reker Hadrup; Jan Strindhall; Tania Køllgaard; Tina Seremet; Boo Johansson; Graham Pawelec; Per thor Straten; Anders Wikby
Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional cytomegalovirus-specific T cells in the very elderly.
Journal of immunology (Baltimore, Md. : 1950) 2006;176(4):2645-53.
2006: Mads Hald Andersen; Rikke B Soerensen; Jürgen C Becker; Per thor Straten
HLA-A24 and survivin: possibilities in therapeutic vaccination against cancer.
Journal of translational medicine 2006;4():38.
2006: Mads Hald Andersen; David Schrama; Per thor Straten; Jürgen C Becker
Cytotoxic T cells.
The Journal of investigative dermatology 2006;126(1):32-41.
2005: Søren Skov; Marianne Terndrup Pedersen; Lars Andresen; Per thor Straten; Anders Woetmann; Niels Odum
Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B.
Cancer research 2005;65(23):11136-45.
2005: T Kollgaard; Søren L Petersen; Sine Reker Hadrup; Tania N Masmas; Tina Seremet; Mads Hald Andersen; Hans O Madsen; Lars L Vindeløv; Per thor Straten
Evidence for involvement of clonally expanded CD8+ T cells in anticancer immune responses in CLL patients following nonmyeloablative conditioning and hematopoietic cell transplantation.
Leukemia 2005;19(12):2273-80.
2005: Mads Hald Andersen; Sine Reker Hadrup; Pia Kvistborg; Jürgen C Becker; Per thor Straten
Spontaneous immunity against Bcl-xL in cancer patients.
Journal of immunology (Baltimore, Md. : 1950) 2005;175(4):2709-14.
2005: Mads Hald Andersen; Pia Kvistborg; Jürgen C Becker; Per thor Straten
Identification of an HLA-A1 restricted CTL epitope from Mcl-1.
Leukemia 2005;19(6):1084-5.
2005: Mads Hald Andersen; Jürgen C Becker; Per thor Straten
Regulators of apoptosis: suitable targets for immune therapy of cancer.
Nature reviews. Drug discovery 2005;4(5):399-409.
2005: Jürgen C Becker; Per thor Straten; Mads Hald Andersen
The paradoxical association between Bcl-2 expression and prognosis: does the immune system make the difference?
Cancer research 2005;65(7):2983.
2005: Mads Hald Andersen; J C Becker; Per thor Straten
The antiapoptotic member of the Bcl-2 family Mcl-1 is a CTL target in cancer patients.
Leukemia 2005;19(3):484-5.
2005: Anders Meier; Sine Reker Hadrup; Inge Marie Svane; Lars Holten-Andersen; Jürgen C Becker; Ib Søndergaard; Mads Hald Andersen; Per thor Straten
Spontaneous T-cell responses against peptides derived from the Taxol resistance-associated gene-3 (TRAG-3) protein in cancer patients.
Cancer immunology, immunotherapy : CII 2005;54(3):219-28.
2005: Mads Hald Andersen; Inge Marie Svane; Pia Kvistborg; Ove Juul Nielsen; Eva Balslev; Sine Reker Hadrup; Jürgen C Becker; Per thor Straten
Immunogenicity of Bcl-2 in patients with cancer.
Blood 2005;105(2):728-34.
2005: Kerstin Otto; Mads Hald Andersen; Andreas O Eggert; Petra Keikavoussi; Lars Østergaard Pedersen; Jörg C Rath; Markus Böck; Eva-B Bröcker; Per thor Straten; Eckhart Kämpgen; Jürgen C Becker
Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin.
Vaccine 2005;23(7):884-9.
2005: Julio E Celis; José M A Moreira; Irina Gromova; Teresa Cabezon; Ulrik Ralfkiaer; Per Guldberg; Per thor Straten; Henning Mouridsen; Esbern Friis; Dorte Holm; Fritz Rank; Pavel Gromov
Towards discovery-driven translational research in breast cancer.
The FEBS journal 2005;272(1):2-15.
2004: Andreas O Eggert; Mads Hald Andersen; Heike Voigt; David Schrama; Eckhart Kämpgen; Per thor Straten; Jürgen C Becker
Characterization of mouse MAGE-derived H-2Kb-restricted CTL epitopes.
European journal of immunology 2004;34(11):3285-90.
2004: Mads Hald Andersen; Joachim Fensterle; Selma Ugurel; Sine Reker Hadrup; Roland Houben; Per Guldberg; Thomas G Berger; Dirk Schadendorf; Uwe Trefzer; Eva-B Bröcker; Ulf R Rapp; Per thor Straten; Jürgen C Becker
Immunogenicity of constitutively active V599EBRaf.
Cancer research 2004;64(15):5456-60.
2004: Mads Hald Andersen; Jürgen C Becker; Per thor Straten
Identification of an HLA-A3-restricted cytotoxic T lymphocyte (CTL) epitope from ML-IAP.
The Journal of investigative dermatology 2004;122(5):1336-7.
2004: Sine Reker Hadrup; Jürgen C Becker; Inge Marie Svane; Elisabeth Ralfkiaer; Per thor Straten; Mads Hald Andersen
HLA-B35-restricted immune responses against survivin in cancer patients.
International journal of cancer. Journal international du cancer 2004;108(6):937-41.
2004: Mads Hald Andersen; Sine Reker Hadrup; Jürgen C Becker; Per thor Straten
The melanoma inhibitor of apoptosis protein: a target for spontaneous cytotoxic T cell responses.
The Journal of investigative dermatology 2004;122(2):392-9.
2004: Sine Reker Hadrup; Anders Meier; Lars Holten-Andersen; Inge Marie Svane; Jürgen C Becker; Per thor Straten; Mads Hald Andersen
Identification of novel survivin-derived CTL epitopes.
Cancer biology & therapy 2004;3(2):173-9.
2003: Mads Hald Andersen; Julie Gehl; Sine Reker Hadrup; Lars Østergaard Pedersen; Jürgen C Becker; Poul F Geertsen; Per thor Straten
Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.
Seminars in cancer biology 2003;13(6):449-59.
2003: Patrick Terheyden; David Schrama; Lars Østergaard Pedersen; Mads Hald Andersen; Eckhart Kämpgen; Per thor Straten; Jürgen C Becker
Longitudinal analysis of MART-1/HLA-A2-reactive T cells over the course of melanoma progression.
Scandinavian journal of immunology 2003;58(5):566-71.
2003: David Schrama; Andreas A O Eggert; Eva-B Bröcker; Lars Østergaard Pedersen; Per thor Straten; Jürgen C Becker
Immunological consequences of the sentinel lymph-node biopsy--lessons from a melanoma patient.
The lancet oncology 2003;4(7):446-7.
2003: Julio E Celis; Pavel Gromov; Irina Gromova; José M A Moreira; Teresa Cabezón; Noona Ambartsumian; Mariam Grigorian; Eugene Lukanidin; Per thor Straten; Per Guldberg; Jirina Bartkova; Jiri Bartek; Jiri Lukas; Claudia Lukas; Anne E Lykkesfeldt; Marja Jäättelä; Peter Roepstorff; Lars Bolund; Torben F Ørntoft; Nils Brünner; Jens Overgaard; Kerstin Sandelin; Mogens Blichert-Toft; Henning Mouridsen; Fritz Rank
Integrating proteomic and functional genomic technologies in discovery-driven translational breast cancer research.
Molecular & cellular proteomics : MCP 2003;2(6):369-77.
2002: David Schrama; Eva Fuchs; Eva-B Bröcker; Per thor Straten; Jürgen C Becker
Identical T-cell receptor transcripts in multiple melanoma metastases.
Cancer research 2002;62(20):5664-7.
2002: Mads Hald Andersen; Henrik Schmidt; Julie Gehl; Hans von der Maase; Per thor Straten
[Immunotherapy of cancer].
Ugeskrift for laeger 2002;164(23):3008-16.
2002: Claudia S Vetter; Veronika Groh; Per thor Straten; Thomas Spies; Eva-B Bröcker; Jürgen C Becker
Expression of stress-induced MHC class I related chain molecules on human melanoma.
The Journal of investigative dermatology 2002;118(4):600-5.
2002: Lars Østergaard Pedersen; Claudia S Vetter; Maria Cristina Mingari; Mads Hald Andersen; Per thor Straten; Eva-B Bröcker; Jürgen C Becker
Differential expression of inhibitory or activating CD94/NKG2 subtypes on MART-1-reactive T cells in vitiligo versus melanoma: a case report.
The Journal of investigative dermatology 2002;118(4):595-9.
2002: David Schrama; Per thor Straten; Eva-B Bröcker; Ralph A Reisfeld; Jürgen C Becker
Cytokine fusion protein treatment.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 2002;160():185-94.
2002: Per Guldberg; Kirsten Grønbaek; Jesper Worm; Per thor Straten; Jesper Zeuthen
Mutational analysis of oncogenes and tumor suppressor genes in human cancer using denaturing gradient gel electrophoresis.
Methods in molecular medicine 2002;68():125-39.
2002: H Knudsen; Kirsten Grønbaek; Per thor Straten; C Gisselø; P Johansen; S Timshel; Olav J Bergmann; Niels Ebbe Hansen; Elisabeth Ralfkiaer
A case of lymphoblastoid natural killer (NK)-cell lymphoma: association with the NK-cell receptor complex CD94/NKG2 and TP53 intragenic deletion.
The British journal of dermatology 2002;146(1):148-53.
2001: Mads Hald Andersen; Petra Keikavoussi; Eva-B Bröcker; Beatrice Schuler-Thurner; M Jonassen; Ib Søndergaard; Per thor Straten; Jürgen C Becker; Eckhart Kämpgen
Induction of systemic CTL responses in melanoma patients by dendritic cell vaccination: cessation of CTL responses is associated with disease progression.
International journal of cancer. Journal international du cancer 2001;94(6):820-4.
2001: Mads Hald Andersen; Lars Østergaard Pedersen; B Capeller; Eva-B Bröcker; Jürgen C Becker; Per thor Straten
Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients.
Cancer research 2001;61(16):5964-8.
2001: David Schrama; Per thor Straten; Wolfgang H Fischer; A D McLellan; Eva-B Bröcker; Ralph A Reisfeld; Jürgen C Becker
Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue.
Immunity 2001;14(2):111-21.
2001: Mads Hald Andersen; Lars Østergaard Pedersen; Jürgen C Becker; Per thor Straten
Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients.
Cancer research 2001;61(3):869-72.
2001: David Schrama; Mads Hald Andersen; Patrick Terheyden; L Schrøder; Lars Østergaard Pedersen; Per thor Straten; Jürgen C Becker
Oligoclonal T-cell receptor usage of melanocyte differentiation antigen-reactive T cells in stage IV melanoma patients.
Cancer research 2001;61(2):493-6.
2001: Per thor Straten; Jesper Zeuthen; Jürgen C Becker; Per Guldberg
T-cell receptor clonotype mapping using denaturing gradient gel electrophoresis : analysis of clonal T-cell responses in melanoma.
Methods in molecular medicine 2001;61():339-51.
2001: Per thor Straten; Per Guldberg; David Schrama; Mads Hald Andersen; U Moerch; Tina Seremet; Claudia Siedel; R A Reisfeld; Jürgen C Becker
In situ cytokine therapy: redistribution of clonally expanded T cells.
European journal of immunology 2001;31(1):250-8.
2000: Jürgen C Becker; Claudia S Vetter; David Schrama; Eva-B Bröcker; Per thor Straten
Differential expression of CD28 and CD94/NKG2 on T cells with identical TCR beta variable regions in primary melanoma and sentinel lymph node.
European journal of immunology 2000;30(12):3699-706.
2000: Jesper Worm; Jirina Bartkova; Alexei F Kirkin; Per thor Straten; Jesper Zeuthen; Jiri Bartek; Per Guldberg
Aberrant p27Kip1 promoter methylation in malignant melanoma.
Oncogene 2000;19(44):5111-5.
2000: U Moerch; David Schrama; Per Guldberg; Tina Seremet; Jesper Zeuthen; Jürgen C Becker; Per thor Straten
Comparative delineation of T cell clonotypes in coexisting syngeneic B16 melanoma.
Cancer immunology, immunotherapy : CII 2000;49(8):426-32.
2000: Per thor Straten; Alexei F Kirkin; E Siim; K Dahlström; K T Drzewiecki; Tina Seremet; Jesper Zeuthen; Jürgen C Becker; Per Guldberg
Tumor infiltrating lymphocytes in melanoma comprise high numbers of T-cell clonotypes that are lost during in vitro culture.
Clinical immunology (Orlando, Fla.) 2000;96(2):94-9.
2000: Patrick Terheyden; Per thor Straten; Eva-B Bröcker; Eckhart Kämpgen; Jürgen C Becker
CD40-ligated dendritic cells effectively expand melanoma-specific CD8+ CTLs and CD4+ IFN-gamma-producing T cells from tumor-infiltrating lymphocytes.
Journal of immunology (Baltimore, Md. : 1950) 2000;164(12):6633-9.
2000: Claudia S Vetter; Per thor Straten; Patrick Terheyden; Jesper Zeuthen; Eva-B Bröcker; Jürgen C Becker
Expression of CD94/NKG2 subtypes on tumor-infiltrating lymphocytes in primary and metastatic melanoma.
The Journal of investigative dermatology 2000;114(5):941-7.
2000: Per thor Straten; Per Guldberg; U Moerch; Jürgen C Becker
Anti-melanocyte T cell responses - methodology versus biology.
The Journal of investigative dermatology 2000;114(4):738-9.
2000: AM Barfoed; TR Petersen; Alexei F Kirkin; Per thor Straten; Mogens H Claesson; Jesper Zeuthen
Cytotoxic T-lymphocyte clones, established by stimulation with the HLA-A2 binding p5365-73 wild type peptide loaded on dendritic cells In vitro, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein.
Scandinavian journal of immunology 2000;51(2):128-33.
1999: Jürgen C Becker; P Guldberg; Jesper Zeuthen; Eva-B Bröcker; Per thor Straten
Accumulation of identical T cells in melanoma and vitiligo-like leukoderma.
The Journal of investigative dermatology 1999;113(6):1033-8.
1999: Per thor Straten; Jürgen C Becker; Per Guldberg; Jesper Zeuthen
In situ T cells in melanoma.
Cancer immunology, immunotherapy : CII 1999;48(7):386-95.
1999: Wolfgang H Fischer; Per thor Straten; Patrick Terheyden; Jürgen C Becker
Function and dysfunction of CD4(+) T cells in the immune response to melanoma.
Cancer immunology, immunotherapy : CII 1999;48(7):363-70.
1999: Alexei F Kirkin; Per thor Straten; MR Hansen; AM Barfoed; Karine N Dzhandzhugazyan; Jesper Zeuthen
Establishment of gp100 and MART-1/Melan-A-specific cytotoxic T lymphocyte clones using in vitro immunization against preselected highly immunogenic melanoma cell clones.
Cancer immunology, immunotherapy : CII 1999;48(5):239-46.
1999: Per thor Straten; Per Guldberg; Kirsten Grønbaek; MR Hansen; Alexei F Kirkin; Tina Seremet; Jesper Zeuthen; Jürgen C Becker
In situ T cell responses against melanoma comprise high numbers of locally expanded T cell clonotypes.
Journal of immunology (Baltimore, Md. : 1950) 1999;163(1):443-7.
1999: Per Guldberg; Per thor Straten; Vibeke Ahrenkiel; Tina Seremet; Alexei F Kirkin; Jesper Zeuthen
Somatic mutation of the Peutz-Jeghers syndrome gene, LKB1/STK11, in malignant melanoma.
Oncogene 1999;18(9):1777-80.
1998: Kirsten Grønbaek; Per thor Straten; Elisabeth Ralfkiaer; Vibeke Ahrenkiel; Mette K Andersen; Niels Ebbe Hansen; Jesper Zeuthen; K Hou-Jensen; Per Guldberg
Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity.
Blood 1998;92(9):3018-24.
1998: Per thor Straten; AM Barfoed; Tina Seremet; Ingvil Saeterdal; Jesper Zeuthen; Per Guldberg
Detection and characterization of alpha-beta-T-cell clonality by denaturing gradient gel electrophoresis (DGGE).
BioTechniques 1998;25(2):244-50.
1998: Kirsten Grønbaek; T Nedergaard; Mette K Andersen; Per thor Straten; Per Guldberg; PH Møller; Jesper Zeuthen; N Ebbe Hansen; K Hou-Jensen; Elisabeth Ralfkiaer
Concurrent disruption of cell cycle associated genes in mantle cell lymphoma: a genotypic and phenotypic study of cyclin D1, p16, p15, p53 and pRb.
Leukemia 1998;12(8):1266-71.
1998: Per thor Straten; Per Guldberg; Tina Seremet; R A Reisfeld; Jesper Zeuthen; Jürgen C Becker
Activation of preexisting T cell clones by targeted interleukin 2 therapy.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(15):8785-90.
1998: Karine N Dzhandzhugazyan; Alexei F Kirkin; Per thor Straten; Jesper Zeuthen
Ecto-ATP diphosphohydrolase/CD39 is overexpressed in differentiated human melanomas.
FEBS letters 1998;430(3):227-30.
1998: Per Guldberg; K Grønbak; Anni Aggerholm; A Platz; Per thor Straten; Vibeke Ahrenkiel; Peter Hokland; Jesper Zeuthen
Detection of mutations in GC-rich DNA by bisulphite denaturing gradient gel electrophoresis.
Nucleic acids research 1998;26(6):1548-9.
1998: Ingvil Saeterdal; Per thor Straten; J H Myklebust; Alexei F Kirkin; Marianne Klemp Gjertsen; Gustav Gaudernack
Generation and characterization of gp100 peptide-specific NK-T cell clones.
International journal of cancer. Journal international du cancer 1998;75(5):794-803.
1998: Per thor Straten; Elisabeth Ralfkiaer; J Hendriks; Tina Seremet; G L Vejlsgaard; Jesper Zeuthen
T-cell receptor variable region genes in cutaneous T-cell lymphomas.
The British journal of dermatology 1998;138(1):3-12.
1997: Per Guldberg; Alexei F Kirkin; K Gronbaek; Per thor Straten; Vibeke Ahrenkiel; Jesper Zeuthen
Complete scanning of the CDK4 gene by denaturing gradient gel electrophoresis: a novel missense mutation but low overall frequency of mutations in sporadic metastatic malignant melanoma.
International journal of cancer. Journal international du cancer 1997;72(5):780-3.
1997: Per Guldberg; Per thor Straten; Anette Birck; Vibeke Ahrenkiel; Alexei F Kirkin; Jesper Zeuthen
Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma.
Cancer research 1997;57(17):3660-3.
1997: Per thor Straten; Alexei F Kirkin; Tina Seremet; Jesper Zeuthen
Expression of transporter associated with antigen processing 1 and 2 (TAP1/2) in malignant melanoma cell lines.
International journal of cancer. Journal international du cancer 1997;70(5):582-6.
1997: Anette Birck; Per thor Straten; L Li; K Hou-Jensen; J Sugár; Jesper Zeuthen
Analysis of T cell receptor AV and BV chain gene expression by infiltrating lymphocytes in Spitz naevi and in halo naevi.
Melanoma research 1997;7(1):49-57.
1996: Per thor Straten; Jürgen C Becker; Tina Seremet; E B Bröcker; Jesper Zeuthen
Clonal T cell responses in tumor infiltrating lymphocytes from both regressive and progressive regions of primary human malignant melanoma.
The Journal of clinical investigation 1996;98(2):279-84.
1996: Alexei F Kirkin; Per thor Straten; Jesper Zeuthen
Differential modulation by interferon gamma of the sensitivity of human melanoma cells to cytolytic T cell clones that recognize differentiation or progression antigens.
Cancer immunology, immunotherapy : CII 1996;42(4):203-12.
1995: Alexei F Kirkin; T R Petersen; A C Olsen; L Li; Per thor Straten; Jesper Zeuthen
Generation of human-melanoma-specific T lymphocyte clones defining novel cytolytic targets with panels of newly established melanoma cell lines.
Cancer immunology, immunotherapy : CII 1995;41(2):71-81.
1994: J Schøller; Per thor Straten; Anette Birck; E Siim; K Dahlström; K T Drzewiecki; Jesper Zeuthen
Analysis of T cell receptor alpha beta variability in lymphocytes infiltrating melanoma primary tumours and metastatic lesions.
Cancer immunology, immunotherapy : CII 1994;39(4):239-48.
1994: Per thor Straten; J Schøller; K Hou-Jensen; Jesper Zeuthen
Preferential usage of T-cell receptor alpha beta variable regions among tumor-infiltrating lymphocytes in primary human malignant melanomas.
International journal of cancer. Journal international du cancer 1994;57(1):138.
1994: Per thor Straten; J Schøller; K Hou-Jensen; Jesper Zeuthen
Preferential usage of T-cell receptor alpha beta variable regions among tumor-infiltrating lymphocytes in primary human malignant melanomas.
International journal of cancer. Journal international du cancer 1994;56(1):78-86.